(A) Body weights of WT and ERRαγAd−/− mice fed a 60% high fat diet (HFD) for 18 weeks (n = 12–18).
(B) Glucose tolerance test (GTT) of WT and ERRαγAd−/− mice fed a 60% HFD and before treatment. Values are presented as percentage of starting blood glucose (WT, 111.7 ±6.1 mg/dL; ERRαγAd−/−, 107.1 ±3.7 mg/dL; p = 0.52), (n = 12–18).
(C) Body weights of WT and ERRαγAd−/− mice before and after treatment with PBS or CL316,243 (n = 6–9). ***p < 0.001.
(D) Body weight loss of WT and ERRαγAd−/− mice, expressed as percentage of body weight before treatment (n = 6–9). *p < 0.01; ***p < 0.001.
(E) GTT of WT mice treated with PBS or CL316,243. Values are presented as percentage of starting blood glucose (WT PBS, 74.3 ± 9.9 mg/dL; WT CL316,243, 99.4 ± 8.2 mg/dL; p = 0.074). (n = 6–9). *p < 0.05, **p < 0.01, ***p < 0.001 vs. WT CL316,243.
(F) GTT of ERRαγAd−/− mice treated with PBS or CL316,243. Values are presented as percentage of starting blood glucose (ERRαγAd−/− PBS, 79.9 ± 4.9 mg/dL; ERRαγAd−/− CL316,243, 75.2 ± 6.2 mg/dL; p = 0.56) (n = 6–9).
Female mice were born and raised at thermoneutrality (30°C) and fed a 60% HFD starting at weaning. At 22 weeks of age, mice were given an intraperitoneal injection of PBS or CL316,243 every other day for 4 weeks. Mice were euthanized at 26 weeks of age. Data are presented as mean ± SEM.